Aurigene肿瘤学报告说,印度成功进行了DRL-1801 CAR-T细胞疗法第一阶段试验,反应率高,没有产生严重的副作用,导致第二阶段试验核准。 Aurigene Oncology reports successful Phase 1 trial for DRL-1801 CAR-T cell therapy in India, showing high response rate and no severe side effects, leading to Phase 2 trial approval.
Dr. Reddy's Laboratories 的子公司 Aurigene Oncology 报告了 Ribrecabtagene autoleucel （DRL-1801） 的 1 期试验结果，这是一种针对印度复发/难治性多发性骨髓瘤的 BCMA 定向 CAR-T 细胞疗法。 Aurigene Oncology, a subsidiary of Dr. Reddy's Laboratories, reported successful Phase 1 trial results for Ribrecabtagene autoleucel (DRL-1801), a BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma in India. 所有8名病人都表现出临床反应,62.5%的病人达到了严格的完全反应,没有观察到严重的副作用。 All eight patients showed clinical response, with 62.5% achieving stringent complete response, and no severe side effects noted. 印度药品总主计长在取得这些积极成果后批准了第二阶段试验。 The Drugs Controller General of India has approved the Phase 2 trial following these positive results.